服务地点对透析通路介入中支架使用的影响
作者指出CMS近年报销政策变化可能改变这一现状,或导致支架使用增加及总体费用上升。
要点
- CMS 2019年报销调整大幅降低ASC内透析通路血管成形报销,同时提高支架设施报销。
- 报销激励可能促使介入医生在ASC中增加支架使用,带来费用上升风险。
核心结论
- 既往报销模式下财务激励尚未对透析通路支架使用产生明显影响,但CMS近期重大变化可能改变这一动态,或导致总体费用显著升高而无证实的临床优势。
研究设计与样本
- 回顾性审查2014至2018年前瞻性维护数据库,纳入在办公室实验室(后为门诊手术中心)和主要医院接受透析通路血管成形及辅助支架置入的所有患者。
主要发现
- 两中心共完成961例透析通路血管成形或支架手术,医院564例(58.7%),门诊397例(41.3%)。
- 两地点种族和年龄存在显著差异,年轻少数族裔患者更常在医院治疗,老年白人患者更常在门诊治疗。
关键数值与推荐
- CMS 2019年对办公室实验室和门诊手术中心手术实施大规模报销变更,门诊手术中心透析通路血管成形报销降低50%,而支架设施报销较前水平增加33%。
临床怎么用
- 介入医生在门诊手术中心进行球囊血管成形时可能受激励增加支架使用,需警惕无临床优势的费用上升。
- 鉴于高失败率和再干预率以及日益昂贵的辅助器械(药物涂层球囊和支架、覆膜支架),激励特定手术类型或地点的费用影响巨大。
局限性
- 本研究为单中心回顾性分析,样本来自作者所在血管组,结果可能受机构实践和患者人群特征影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: With rising health care spending in the United States, the Centers for Medicare and Medicaid Services (CMS) in recent years attempted to use reimbursement rates to influence use of less expensive care sites for covered patients, such as ambulatory surgery centers (ASCs) and office-based laboratories (OBLs), in lieu of hospital service sites. It has been suggested that cost savings have not been realized because of more procedures being performed by physicians with ownership interests in nonhospital facilities. CMS adopted massive reimbursement changes for 2019 OBL and ASC-based procedures, which reduced dialysis access angioplasty reimbursement in the ASC setting by 50%, whereas facility reimbursement for stenting increased by 33% above prior levels. The clinical utility of adjunctive stenting in treating dialysis access stenosis remains controversial and highly discretionary. As a vascular group performing such procedures in both a hospital and nonhospital facility in which we have equity interest, we reviewed our use of stents in dialysis access procedures both in the hospital and in the ASC/OBL to determine whether site of service affected stent use. METHODS: A retrospective review of a prospectively maintained database was performed from 2014 to 2018. All patients undergoing dialysis access angiography with angioplasty and adjunctive stent placement at our OBL (later ASC) and our primary hospital were included in the study. RESULTS: There were 961 angioplasty or stent procedures performed for dialysis accesses between the two sites, 564 (58.7%) in the hospital setting and 397 (41.3%) at the OBL/ASC. There was a significant difference in race and age between the two sites, with younger, minority patients more frequently being treated in the hospital and older, white patients more likely to be treated in the ambulatory setting; 153 (27.1%) underwent adjunctive stent placement in the hospital and 127 (32.0%) in the ambulatory setting (P = .09). CONCLUSIONS: Whereas financial incentives have not yet had an appreciable influence on stent use for dialysis access within previous reimbursement paradigms, the dramatic changes recently adopted by CMS may well alter this dynamic and could lead to substantially higher overall costs without proven clinical advantage. Interventionalists may be incentivized to add stents when performing balloon angioplasty in ASCs. With high failure and reintervention rates and increasingly expensive adjuncts (drug-coated balloons and stents, covered stents), the cost implications of attempts to incentivize interventionalists toward a specific type of procedure or site of care are substantial, and unintended negative consequences are likely to occur.
引用
- Madden NJ, Dougherty MJ, Troutman DA, et al. Site of service influence on stent use for hemodialysis access interventions. J Vasc Surg. 2019. PMID: 31708303. doi:10.1016/j.jvs.2019.06.219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。